Design and analysis of bioavailability and bioequivalence studies, third edition

Design and Analysis of Bioavailability and Bioequivalence Studies, Third Edition

Volumn , Issue , 2008, Pages 1-735

  Chow, Shein Chung ^a   Liu, Jen Pei ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057258806     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (445)

1. Aarons, L. 1991. Population pharmacokinetics: theory and practice. Br. J. Clin. Pharmacol., 32, 669–670.
2. Agresti, A. 1990. Categorical Data Analysis. 1st ed., John Wiley & Sons, New York.
3. Agresti, A. 2002. Categorical Data Analysis. 2nd ed., John Wiley & Sons, New York.
4. Al-Banna, M.K., Kelman, A.W., and Whiting, B. 1990. Experimental design and efficient parameter estimation in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 18, 347–360.
5. Albert, K.S. and Smith, R.B. 1980. Bioavailability assessment as influenced by variations in drug absorption. In: Drug Absorption and Disposition: Statistical Considerations, Albert, K.S. (Ed.), American Pharmaceutical Association, Washington, DC, pp. 87–113.
6. Altham, P.M.E. 1971. The analysis of matched proportions. Biometrika, 58, 561–576.
7. Amidon, G.L., Lennernas, H., Shah, V.P., and Crison, J.R. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12, 413–420.
8. Anderson, R.L. 1982. Analysis of Variance Components, Unpublished Lecture Notes. University of Kentucky, Lexington, KY.
9. Anderson, S. 1993. Individual bioequivalence: A problem of switchability [with discussion]. Biopharmaceutical Report, 2, 1–11.
10. Anderson, S. and Hauck, W.W. 1983. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Communications in Statistics—Theory and Methods, 12, 2663–2692.
11. Anderson, S. and Hauck, W.W. 1990. Consideration of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics, 18, 259–273.
12. Armitage, P. and Berry, G. 1987. Statistical Methods in Medical Research. 2nd ed., Blackwell Scientific, Oxford, UK.
13. 2 experimental units. Biometrics, 24, 61–73.
14. Balant, L.P. 1991. Is there a need for more precise definitions of bioavailability? European Journal of Clinical Pharmacology, 40, 123–126.
15. Beal, S.L. and Sheiner, L.B. 1980. The NONMEM system. American Statistician, 34, 118–119.
16. Beal, S.L. and Sheiner, L.B. 1982. Estimating population pharmacokinetics. Critical Reviews in Biomedical Engineering, 8, 195–222.
17. Beal, S.L. and Sheiner, L.B. 1989. NONMEM, User’s Guide. NONMEM Project Group, University of California, San Francisco, CA.
18. Beckhofer, R.E., Dunnett, C.W., and Sobel, M. 1954. A two sample multiple decision procedure for linking means of normal populations with a common unknown variance. Biometrika, 41, 170–176.
19. Bellavance, F. and Tardif, S. 1995. A nonparametric approach to the analysis of three-treatment three-period crossover design. Biometrika, 82, 865–875.
20. Benet, L.Z. and Goyan, J.E. 1995. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy, 15, 433–440.
21. Berger, R.L. 1982. Multiparametric hypothesis testing and acceptance sampling. Technometrics, 24, 295–300.
22. Bickel, P.J. and Doksum, A.D. 1977. Mathematical Statistics. Holden-Day, San Francisco, CA.
23. Blackwelder, W.C. 1982. Proving the null hypothesis in clinical trials. Controlled Clinical Trials, 3, 345–353.
24. Blume, H.H. and Midha, K.K. 1993a. Conference Report. In: Bio-International: Bioavailability, Bioequivalence and Pharmacokinetics, Blume, H.H. and Midha, K.K. (Eds.), Medpharm, Stuttgart, Germany, pp. 13–23.
25. Blume, H.H. and Midha, K.K. 1993b. Bio-international 92, conference on bioavailability, bioequivalence and pharmacokinetic studies. Pharmaceutical Research, 10, 1806–1811.
26. Boardman, T.J. 1974. Confidence intervals for variance components—a comparative Monte Carlo study. Biometrics, 30, 251–262.
27. Bose, R.C., Clatworthy, W.H., and Shrinkhande, S. 1954. Tables of partially balanced incomplete block design with two associate classes. Journal of the American Statistical Association, 47, 151–184.
28. Box, G.E.P. and Tiao, G.C. 1973. Bayesian Inference in Statistical Analysis. Addison-Wesley, Reading, MA.
29. Bradu, D. and Mundlak, Y. 1970. Estimation in lognormal linear model. Journal of the American Statistical Association, 65, 198–211.
30. Brown, B.W. 1980. The crossover experiment for clinical trials. Biometrics, 36, 69–79.
31. Brown, L.D., Hwang, J.T.G., and Munk, A. 1998. An unbiased test for the bioequivalence problem. Annals of Statistics, 25, 2345–2367.
32. Buonaccorsi, J.P. and Gatsonis, C.A. 1988. Bayesian inference for ratios of coefficients in a linear model. Biometrics, 44, 87–101.
33. Carrasco, J.L. and Jover, L. 2002. Assessing individual bioequivalence using the structural equation model. Statistics in Medicine, 22, 901–912.
34. Chen, K.W., Li, G., Sun, Y., and Chow, S.C. 1996. A confidence region approach for assessing equivalence in variability of bioavailability. Biometrical Journal, 38, 475–487.
35. Chen, K.W., Li, G., Sun, Y., and Chow, S.C. 1997a. Internal estimation for ratios in bioequivalence trials. Biometrical Journal, 39, 989–1002.
36. Chen, K.W., Li, G., and Chow, S.C. 1997b. A note on sample size determination for bioequivalence studies with higher-order crossover designs. Journal of Pharmacokinetics and Pharmacodynamics, 25, 753–765.
37. Chen, M.L. 1995. Individual bioequivalence. Invited presentation at International Workshop: Statistical and Regulatory Issues on the Assessment of Bioequivalence. Dusseldorf, Germany, October 19–20.
38. Chen, M.L. 1996. Individual bioequivalence criterion. Presented at the meeting of the Advisory Committee for Pharmaceutical Sciences. Gaitherburg, Maryland, August 15–16.
39. Chen, M.L. 1997. Individual bioequivalence—a regulatory update. Journal of Biopharmaceutical Statistics, 7, 5–11.
40. Chen, M.L. and Pelsor, F.R. 1991. Half-life revisited: Implication in clinical trials and bioavailability=bioequivalence evaluation. Journal of the American Pharmacists Association, 80, 406–408.
41. Chen, M.L., Patnaik, R., Hauck, W.W., Schuirmann, D.F., Hyslop, T., and Williams, R. 2000. An individual bioequivalence criterion—regulatory considerations. Statistics in Medicine, 19, 2821–2842.
42. Chen, M.L., Patnaik, R., Hauck, W.W., Schuirmann, D.J., Hyslop, T., and Williams, R. 2000. An individual bioequivalence criterion: Regulatory considerations. Statistics in Medicine, 19, 2821–2842.
43. Chen, M.L., Shah, V., Patnaik, R., Adams, W., Hussain, A., Conner, D., Mehta, M., Malinowski, H., Lazor, J., Huang, S.M., Hare, D., Lesko, L., Sporn, D., and Williams, R. 2001a. Bioavailability and bioequivalence: An FDA regulatory overview. Pharmaceutical Research, 18, 1645–1650.
44. Chen, M.L., Lesko, L., and Williams, R.L. 2001b. Measures of exposure versus measures of rate and extent of absorption. Clinical Pharmacokinetics, 40, 565–572.
45. Cheng, C.L. and Van Ness, J.W. 1999. Statistical Regression with Measurement Error. Arnold, London.
46. Cheng, C.S. and Wu, C.F. 1980. Balanced repeated measurements designs. Annals of Statistics, 8, 1272–1283 (Corrigendum, 11, p. 349 [1983]).
47. Chinchilli, V.M. 1996. The assessment of individual and population bioequivalence. Journal of Biopharmaceutical Statistics, 6, 6–14.
48. Chinchilli, V.M. and Durham, B.S. 1989. Testing for bioequivalence via R-estimation. Presented at the 45th Conference on Applied Statistics, Atlantic City, NJ.
49. Chinchilli, V.M. and Esinhart, J.D. 1994. Extension to the use of tolerance interval for the assessment of individual bioequivalence. Journal of Biopharmaceutical Statistics, 4, 39–52.
50. Chinchilli, V.M. and Esinhart, J.D. 1996. Design and analysis of intra-subject variability in cross-over experiments. Statistics in Medicine, 15, 1619–1634.
51. Chow, S.C. 1985. Resampling procedures for the estimation of non-linear functions of parameters. Ph.D. Thesis. University of Wisconsin, Madison, WI.
52. Chow, S.C. 1989. Some results on bioavailability=bioequivalence studies. Proceedings of the Biopharmaceutical section of the American Statistical Association, Washington, D.C., pp. 260–268.
53. Chow, S.C. 1990. Alternative approaches for assessing bioequivalence regarding normality assumptions. Drug Information Journal, 24, 753–762 (Corrigendum, 25, p. 161 [1991]).
54. Chow, S.C. 1995. Ed. Bioavailability and bioequivalence. Drug Information Journal, 29 (3; special issue), 793–1068.
55. Chow, S.C. 1996a. Issues in bioequivalence. Biopharmaceutical Report, 4, 1–12.
56. Chow, S.C. 1996b. Statistical considerations for replicated design. In: Bioavailability, Bioequivalence and Pharmacokinetic Studies. Proceedings of FIP Bio-International’96. Midha, K.K. and Nagai, T. (Eds.), Business Center for Academic Societies, Tokyo, Japan, pp. 107–112.
57. Chow, S.C. 1997a. Ed. Recent issues in bioequivalence trials. Journal of Biopharmaceutical Statistics, 7 (1; special issue), 1–204.
58. Chow, S.C. 1999. Individual bioequivalence—a review of the FDA draft guidance. Drug Informational Journal, 33, 435–444.
59. Chow, S.C. and Ju, H.L. 1994. Bioequivalence: A review and prospects for the future. Journal of Chinese Statistical Association, 32, 179–196.
60. Chow, S.C. and Ki, F. 1997. Statistical comparison between dissolution profiles of drug products. Journal of Biopharmaceutical Statistics, 7, 241–258.
61. Chow, S.C. and Liu, J.P. 1992. On assessment of bioequivalence under a higher-order crossover design. Journal of Biopharmaceutical Statistics, 2, 239–256.
62. Chow, S.C. and Liu, J.P. 1994a. Statistical considerations in bioequivalence trials. Communications in Statistics—Theory and Methods, 23, 289–304.
63. Chow, S.C. and Liu, J.P. 1994b. Recent statistical development in bioequivalence trials—a review of FDA guidance. Drug Information Journal, 28, 851–864.
64. Chow, S.C. and Liu, J.P. 1995a. Current issues in bioequivalence trials. Drug Information Journal, 29, 795–804.
65. Chow, S.C. and Liu, J.P. 1995b. Statistical Design and Analysis in Pharmaceutical Science. Marcel Dekker, New York.
66. Chow, S.C. and Liu, J.P. 1997. Meta-analysis for bioequivalence review. Journal of Biopharmaceutical Statistics, 7, 97–111.
67. Chow, S.C. and Liu, J.P 2000. Design and Analysis of Bioavailability and Bioequivalence Studies, 2nd Ed., Marcel Dekker, New York.
68. Chow, S.C. and Liu, J.P. 2004. Design and Analysis of Clinical Trials. 2nd edn. John Wiley & Sons, New York.
69. Chow, S.C. and Shao, J. 1988. A new procedure for the estimation of variance components. Statistics and Probability Letters, 6, 349–355.
70. Chow, S.C. and Shao, J. 1989. Tests for batch-to-batch variation in stability analysis. Statistics in Medicine, 8, 883–890.
71. Chow, S.C. and Shao, J. 1990. An alternative approach for the assessment of bioequivalence between two formulation of a drug. Biometrical Journal, 32, 969–976.
72. Chow, S.C. and Shao, J. 1991. A note on decision rules in bioequivalence studies. Unpublished manuscript.
73. Chow, S.C. and Shao, J. 1997. Statistical methods for two-sequence three-period cross-over designs with incomplete data. Statistics in Medicine, 16, 1031–1039.
74. Chow, S.C. and Shao, J. 1999. Bioequivalence review for drug interchangeability. Journal of Biopharmaceutical Statistics, 9, 485–497.
75. Chow, S.C. and Shao, J. 2002. Statistics in Drug Research–Methodologies and Recent Developments. Marcel Dekker, New York.
76. Chow, S.C., Cheng, J., and Shao, J. 1990. A nonparametric bootstrap approach for assessing bioequivalence. Unpublished manuscript.
77. Chow, S.C., Peace, K., and Shao, J. 1991. Assessment of bioequivalence using multiplicative model. Journal of Biopharmaceutical Statistics, 1, 193–203.
78. Chow, S.C., Shao, J., and Wang, H. 2002a. Individual bioequivalence testing under 2x3 designs. Statistics in Medicine, 21, 629–648.
79. Chow, S.C., Shao, J., and Wang, H. 2002b. Statistical tests for population bioequivalence. Statistica Sinica, 13, 539–554.
80. Chow, S.C., Shao, J., and Wang, H. 2003a. In vitro bioequivalence testing. Statistics in Medicine, 22, 55–68.
81. Chow, S.C., Shao, J., and Wang, H. 2003b. Sample Size Calculation in Clinical Research. Marcel Dekker, New York.
82. Chow, S.C., Shao, J., and Li, L. 2004. Assessing bioequivalence using genomic data. Journal of Biopharmaceutical Statistics, 14, 869–880.
83. Chow, S.C. and Tse, S.K. 1988. Intrasubject variability estimation in bioavailability= bioequivalence studies. Proceedings of the Biopharmaceutical Section of the American Statistical Association, pp. 142–147, Chicago, Illinois.
84. Chow, S.C. and Tse, S.K. 1990a. Outlier detection in bioavailability=bioequivalence studies. Statistics in Medicine, 9, 549–558.
85. Chow, S.C. and Tse, S.K. 1990b. A related problem in bioavailability=bioequivalence studies—estimation of intrasubject variability with a common CV. Biometrical Journal, 32, 597–607.
86. Clayton, D. and Leslie, A. 1981. The bioavailability of erythromycin stearate versus enteric-coated erythromycin based when taken immediately before and after food. Journal of International Medical Research, 9, 470–477.
87. Cochran, W.G. and Cox, G.M. 1957. Experimental Designs. 2nd ed., John Wiley & Sons, New York.
88. Colton, T. 1974. Statistics in Medicine. Little, Brown, and Company, Boston, MA.
89. Cook, R.D. and Weisberg, S. 1982. Residuals and Influence in Regression. Chapman & Hall, New York and London.
90. Cornell, R.G. 1980. Evaluation of bioavailability data using nonparametric statistics. In: Drug Absorption and Disposition: Statistical Considerations, Albert, K.S. (Ed.), American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Washington DC, pp. 51–57.
91. Cornell, R.G. 1990. The evaluation of bioequivalence using nonparametric procedures. Communications in Statistics—Theory and Methods, 19, 4153–4165.
92. Cox, D.R. and Reid, N. 2000. The Theory of the Design of Experiments. Chapman & Hall=CRC, New York.
93. Crow, E.L. and Shimizu, K. 1988. Lognormal Distribution. Marcel Dekker, New York.
94. Dare, J.G. 1964. Particle size in relation to formulation. Australian Journal of Pharmacology, 45, S58.
95. Davidian, M. 2003. What’s in between dose and response? Lecture notes. Myrto Lefkopoulou Lecture.
96. Davidian, M. and Gallant, A.R. 1993. The nonlinear mixed effects model with a smooth random effects density. Biometrika, 80, 475–488.
97. Davidian, M. and Giltinan, D.M. 1995. Nonlinear Models for Repeated Measurement Data. Chapman & Hall, London, UK.
98. Dempster, A.P., Laird, N.M., and Rubin, D.B. 1977. Maximum likelihood from incomplete data via EM algorithm. Journal of the Royal Statistical Society Series B, 39, 1–38.
99. DerSimonian, R. and Laird, N. 1986. Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177–188.
100. Diggle, P.J., Liang, K.Y. and Zeger, S.L. 1994. Analysis of Longitudinal Data. Oxford Science, Oxford, UK.
101. Diletti, E., Hauschke, D., and Steinijans, V.W. 1991. Sample size determination for bioequivalence assessment by means of confidence interval. International Journal of Clinical Pharmacology, Therapy and Toxicology, 29, 1–8.
102. Draglin, V., Fedorov., V., Patterson, S., and Jones, B. 2003. Kullback–Leibler divergence for evaluation bioequivalence. Statistics in Medicine, 22, 913–930.
103. Draper, N.R. and Smith, H. 1981. Applied Regression Analysis. 2nd ed., John Wiley & Sons, New York.
104. Drug Bioequivalence Study Panel 1974. Drug Bioequivalence. A report from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States, prepared by Family Health Care, Inc., Washington, DC under contract OTAC-1 with the Office of Technology Assessment, Congress of the United States.
105. Dubey, S. 1988. Regulatory considerations on meta-analysis, dentifrice studies and multi-center trials. Proceedings of the Biopharmaceutical Section of the American Statistical Association, pp. 18–27 Chicago, Illinois.
106. Dunnett, C.W. and Gent, M. 1977. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2 x 2 tables. Biometrics, 33, 593–602.
107. Eaton, M.L., Muirhead, R.J., and Steeno, G.S. 2003. Aspects of the dissolution profile testing problem. Biopharmaceutical Report, 11, 2–7.
108. Edler, L. 1998. List of PK–PD software packages. http:==www.dkfz-heidelberg.de=biostatistics= pkpd=pkcomp1=html, Heidelberg, Germany.
109. Edwards, W., Lindman, H., and Savage, L.J. 1963. Bayesian statistical inference for psychological research. Psychological Review, 70, 193.
110. Efron, B. 1982. The Jackknife, Bootstrap and Other Resampling Plans. SIAM, Philadelphia, PA.
111. Efron, B. and Tibshirani, R.J. 1993. An Introduction to the Bootstrap. Chapman & Hall, New York.
112. Ekbohm, G. and Melander, H. 1989. The subject-by-formulation interaction as a criterion of interchangeability of drugs. Biometrics, 45, 1249–1254.
113. Endrenyi, L. 1981. Design of experiments for estimating enzyme and pharmacokinetic experiments. In: Kinetic Data Analysis of Enzyme and Pharmacokinetic Experiments, Endrenyi, L. (Ed.), Plenum Press, New York.
114. Endrenyi, L. 1994. A method for the evaluation of individual bioequivalence. International Journal of Clinical Pharmacology and Therapeutics, 32, 497–508.
115. Endrenyi, L. and Hao, Y. 1998. Asymmetry of the mean-variability tradeoff raises question about the model in investigations of individual bioequivalence. International Journal of Clinical Pharmacology, Therapy and Toxicology, 36, 1–8.
116. Endrenyi, L. and Midha, K.K. 1998. Individual bioequivalence—has its time come? European Journal of Pharmaceutical Sciences, 6, 271–277.
117. Endrenyi, L. and Tothfalusi, L. 1999. Subject-by-formulation interaction in determination of individual bioequivalence: Bias and prevalence. Pharmaceutical Research, 16, 186–190.
118. Endrenyi, L., Fritsch, S., and Yan, W. 1991. (C)=AUC is a clearer measure than (C) for max max absorption rates in investigations of bioequivalence. International Journal of Clinical Pharmcology, Therapy and Toxicology, 29, 394–399.
119. Endrenyi, L., Amidon, G.L., Midha, K.K., and Skelly, J.P. 1998. Individual bioequivalence: Attractive in principle, difficulty in practice. Pharmaceutical Research, 15, 1321–1325.
120. Endrenyi, L., Taback, N., and Tothfalusi, L. 2000. Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence. Statistics in Medicine, 19, 2867–2878.
121. Esinhart, J.D. and Chinchilli, V.M. 1990. Statistical inference on intra-subject variability in bioequivalence studies. Proceedings of the Biopharmaceutical Section of the American Statistical Association, pp. 37–42, Anaheim, California.
122. Esinhart, J.D. and Chinchilli, V.M. 1991. The analysis of bioequivalence studies using generalized estimating equations. Presented at the 1991 ENAR Meeting of the Biometric Society, Houston, TX.
123. Esinhart, J.D. and Chinchilli, V.M. 1994a. Extension to the use of the tolerance intervals for the assessment of individual bioequivalence. Journal of Biopharmaceutical Statistics, 4, 39–52.
124. Esinhart, J.D. and Chinchilli, V.M. 1994b. Sample size considerations for assessing of individual bioequivalence on the method of tolerance intervals. International Journal of Clinical Pharmacology and Therapeutics, 32, 26–32.
125. Ette, E.L., Sun, H., and Ludden, T.M.1994. Design of population pharmacokinetic studies. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 487–492.
126. The European Agency for the Evaluation of Medicinal Products (EMEA) 2001. Note for Guidance on the Investigation of Bioavailability and Bioequivalence, London, UK.
127. EMEA 2003a. Note for Guidance on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Drug Substance—Non Clinical and Clinical Issues. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA=CHMP=3097=02, London, UK.
128. EMEA 2003b. Revision 1 Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Drug Substance—Quality Issues. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA=CHMP= BWP=3207=00=Rev 1, London, UK.
129. EMEA 2005a. Guideline on Similar Biological Medicinal Products. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA=CHMP=437=04, London, UK.
130. EMEA 2005b. Draft Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Drug Substance: Quality Issues. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA=CHMP=49348=05, London, UK.
131. EMEA 2005c. Draft Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Drug Substance—Non Clinical and Clinical Issues—Guidance on Biosimilar Medicinal Products Containing Recombinant Erythro-poietins. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA=CHMP=94526=05, London, UK.
132. EMEA 2005d. Draft Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Drug Substance—Non Clinical and Clinical Issues—Guidance on Biosimilar Medicinal Products Containing Recombinant Granulo-cyte-Colony Stimulating Factor. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA=CHMP=31329=05, London, UK.
133. EMEA 2005e. Draft Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Drug Substance—Non Clinical and Clinical Issues— Guidance on Biosimilar Medicinal Products Containing Somatropin. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA=CHMP=94528=05, London, UK.
134. EMEA 2005f. Draft Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Drug Substance—Non Clinical and Clinical Issues—Guidance on Biosimilar Medicinal Products Containing Recombinant Human Insulin. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA=CHMP=32775=05, London, UK.
135. EMEA 2005g. Guideline on the Clinical Investigating of the Pharmacokinetics of Therapeutic proteins. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA=CHMP=89249=04, London, UK.
136. EMEA 2006. Concept Paper for an Addendum to the Note for Guidance on the Investigation of Bioavailability and Bioequivalence: Evaluation of Bioequivalence of Highly Variable Drugs and Drug Products, London, UK.
137. FDA 1992. Guidance on Statistical Procedures for Bioequivalence Using a Standard Two-treatment Crossover Design, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
138. FDA 1995a. SUPAC-IR: Guidance on Immediate Release Solid Dosage Forms, Scale-up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
139. FDA 1995b. Guidance on Topical Dermatologic Corticosteriods: In Vivo Bioequivalence, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
140. FDA 1997a. SUPAC-MR: Guidance on Modified Release Solid Dosage Forms, Scale-up and Post-Approval Changes: Chemistry, Manufacturing and Controls, for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
141. FDA 1997b. Dissolution Testing of Immediate Release Solid Oral Dosage Forms, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
142. FDA 1997c. Draft Guidance on In Vivo Bioequivalence Studies Based on Population and Individual Bioequivalence Approaches, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
143. FDA 1998. Data Sets of Bioequivalence for Individual and Population Bioequivalence. Published on Internet: www.fda.gov=cder=bioeuivdata= index.htm.
144. FDA 1999a, Guidance for Industry on Average Population and Individual Approaches to Establishing Bioequivalence. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland.
145. FDA 1999b. Guidance for Industry—Population Pharmacokinetics. Center for Drug Research and Evaluation, the United States Food and Drug Administration, Rockville, Maryland.
146. FDA 1999c, Guidance for Industry on Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland.
147. FDA 1999d, Guidance for Industry on Nasal Spray and Inhalation Solution, Suspension and Spray Drug Products. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland.
148. FDA 2000. Guidance on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
149. FDA 2001. Guidance on Statistical Approaches to Establishing Bioequivalence, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
150. FDA 2003a. Guidance on Food-Effect Bioavailability and Fed Bioequivalence Studies, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
151. FDA 2003b. Guidance on Bioavailability and Bioequivalence Studies for Orally Administrated Drug Products—General Considerations, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
152. FDA 2003c. Second Draft Guidance on Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
153. FDA 2003d. Statistical Information from the June 1999 Draft Guidance and Statistical Information for In Vitro Bioequivalence Data Posted on August 18, 1999, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
154. FDA 2003e. Guidance on Clozapine Tablets: In Vivo Bioequivalence and In Vitro Dissolution Testing, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
155. FDA 2004. Challenge and Opportunity on the Critical Path to New Medicinal Products. http:==www.fda.gov=oc=initiatives=criticalpath=whitepaper.pdf.
156. FDA 2006a. Challenge and Opportunity on the Critical Path to New Medicinal Products. http:==www.fda.gov=oc=initiatives=criticalpath=whitepaper.pdf.
157. FDA 2006b. Critical Path Opportunities List. http:==www.fda.gov=oc=initiatives=criticalpath= reports=opp_list.pdf.
158. FDA 2006c. Premarket Approval. http:==www.fda.gov=cdrh=devadvice=pma.
159. FDA 2006d. Premarket Notification 510 (k). http:==www.fda.gov=CDRH=DEVADVICE=314.html.
160. FDA 2007. Critical Path Opportunities for Generic Drugs. http:==www.fda.gov=oc=initiatives= criticalpath=reports=generic=html.
161. Feingold, M. and Gillespie, B.W. 1996. Cross-over trials with censored data. Statistics in Medicine, 15, 953–967.
162. Feinstein, A.R. 2002. Principles of Medical Statistics. Chapman & Hall=CRC, New York.
163. Ferguson, T.S. 1967. On the rejection of outliers. Proceedings of the Fourth Berkeley Symposium on Mathematical Statistics and Probability, Vol. 1, 253–287, Berkeley and Los Angeles: University of California Press, Berkeley, California.
164. Fieller, E. 1954. Some problems in interval estimation. Journal of Royal Statistical Society Series B, 16, 175–185.
165. Fisher, R.A. and Yates, F. 1953. Statistical Tables for Biological, Agricultural, and Medical Research. 4th ed., Oliver and Boyd, Edinburgh, UK.
166. Fleming, T.R. 2000. Design and interpretation of equivalence trials. American Heart Journal, 139, S172–S176.
167. Fluehler, H., Grieve, A.P., Mandallaz, D., Mau, J., and Moser, H.A. 1983. Bayesian approach to bioequivalent assessment: An example. Journal of Pharmaceutical Science, 72, 1178–1181.
168. Fluehler, H., Hirtz, J., and Moser, H.A. 1981. An aid to decision-making in bioequivalence assessment. Journal of Pharmacokinetics and Pharmacodynamics, 9, 235–243.
169. France, L.A., Lewis, J.A., and Kay, R. 1991. The analysis of failure time data in crossover studies. Statistics in Medicine, 10, 1099–1113.
170. Frank, R.G. 2007. Regulation of follow-on biologics. New England Journal of Medicine, 357, 841–843.
171. Frick, H. 1987. On level and power of Anderson and Hauck’s procedure for testing equivalence in comparative bioavailability. Communications in Statistics—Theory and Methods, 16, 2771–2778.
172. Gibaldi, M. and Perrier, D. 1982. Pharmacokinetics. Marcel Dekker, New York.
173. Ghosh, P. and Khattree, R. 2003. Bayesian approach to average bioequivalence using Bayes’ factor. Journal of Biopharmaceutical Statistics, 13, 719–734.
174. Gill, J.L. 1998. Repeated measurement: Split-plot trend analysis versus analysis of first differences. Biometrics, 44, 289–297.
175. Gould, A.L. 1995. Group sequential extensions of standard bioequivalence testing procedure. Journal of Pharmacokinetics and Biopharmaceutics, 23, 57–85.
176. Grahnen, A., Hammerlund, M., and Lundquist, T. 1980. Implication of intrasubject variability in bioavailability studies of furosemide. European Journal of Clinical Pharmacology, 27, 595–602.
177. Graybill, F.A. 1961. An Introduction to Linear Statistical Models. McGraw-Hill, New York.
178. Graybill, F.A. 1976. Theory and Application of the Linear Model. Duxbury, Boston.
179. Graybill, F.A. and Wang, C.M. 1980. Confidence intervals on nonnegative linear combinations of variances. Journal of the American Statistical Association, 75, 869–873.
180. Grieve, A.P. 1985. A Bayesian analysis of the two-period crossover design for clinical trials. Biometrics, 21, 467–480.
181. Grizzle, J.E. 1965. The two-period changeover design and its use in clinical trials. Biometrics, 21, 467–480.
182. Grizzle, J.E. and Allen, D.M. 1969. Analysis of growth and dose response curves. Biometrics, 25, 357–480.
183. Guidelines for Biopharmaceutical Studies in Man, American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Washington, DC, 1972, Appendix I, p. 17.
184. Guilbaud, O. 1993. Exact inference about the within-subject variability in 2 x 2 crossover study. Journal of the American Statistical Association, 88, 939–946.
185. Halperin, M. 1961. Almost linearly-optimum combination of unbiased estimates. Journal of the American Statistical Association, 56, 36–43.
186. Hashimoto, Y. and Sheiner, L.B. 1991. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. Journal of Pharmacokinetics and Biopharmaceutics, 19, 333–353.
187. Hauck, W.W. 1996a. Mean difference vs. variability reduction: Tradeoffs in aggregate measures for individual bioequivalence. International Journal of Clinical Pharmacology, Therapy and Toxicology, 34, 535–541.
188. Hauck, W.W. 1996b. Individual bioequivalence: Concepts. Presented at the Meeting of the Advisory Meeting for Pharmaceutical Science, Holiday Inn, Gaithersburg, Maryland, August 15.
189. Hauck, W.W. and Anderson, S. 1984. A new statistical procedure for testing equivalence in two-group comparative bioavailability trials. Journal of Pharmacokinetics and Biopharmaceutics, 12, 83–91.
190. Hauck, W.W. and Anderson, S. 1992. Types of bioequivalence and related statistical considerations. International Journal of Clinical Pharmacology, Therapy and Toxicology, 30, 181–187.
191. Hauck, W.W. and Anderson, S. 1994. Measuring switchability and prescriptability: When is average bioequivalence sufficient? Journal of Pharmacokinetics and Biopharmaceutics, 22, 551–564.
192. Hauck, W.W., Bois, F.Y., Hyslop, T., Gee, L., and Anderson, S. 1997. A parametric approach to population bioequivalence. Statistics in Medicine, 16, 441–454.
193. Hauck, W.W., Chen, M.L., Tyslop, T., Patnaik, R., Schuirmann, D., and Williams, R. 1996. Mean difference vs. variability reduction: Tradeoff in aggregate measures for individual bioequivalence? International Journal of Clinical Pharmacology, Therapy and Toxicology, 30, 181–187.
194. Hauck, W.W., Tyslop, T., Chen, M.L., Patnaik, R., Williams, R., and the FDA Population= Individual Bioequivalence Working Group. 2000. Subject-by-formulation interaction in bioequivalence: Concept and statistical issues, Pharmaceutical Research, 375–380.
195. Hauschke, D., Steinijans, V.W., and Diletti, E. 1990. A distribution-free procedure for the statistical analyses of bioequivalence studies. International Journal of Clinical Pharmacology, Therapy and Toxicology, 28, 72–78.
196. Hawkins, P.M. 1980. Identification of Outliers. Chapman & Hall, New York.
197. Haynes, J.D. 1981. Statistical simulation study of new proposed uniformity requirements for bioequivalency studies. Journal of Pharmaceutical Sciences, 70, 673–675.
198. Herson, J. 1991. Statistical controversies in design and analysis of bioequivalence trials for pharmaceuticals with negligible blood levels: The metered dose inhaler trial. Presented at the 14th Midwest Biopharmaceutical Statistics Workshop, Muncie, IN.
199. Hills, M. and Armitage, P. 1979. The two-period cross-over clinical trial. British Journal of Clinical Pharmacology, 8, 7–20.
200. Hinkley, D.V. 1969. On the ratio of two correlated normal variables. Biometrika, 56, 635–639.
201. Ho, I. and Patel, H.I. 1988. Comparison of variances in a bioequivalence study. Presented at the American College of Clinical Pharmacology. 17th Annual Meeting Orlando, FL.
202. Hochberg, Y. and Tamhane, A.C. 1987. Multiple Comparison Procedures. John Wiley & Sons, New York.
203. Hocking, R.P. 1985. The Analysis of Linear Models. Brooks=Cole, Monterey, CA.
204. Hodges, J.L. and Lehmann, E.L. 1963. Estimates of location based on rank tests. The Annals of Mathematical Statistics, 34, 598–611.
205. Holder, D.J. and Hsuan, F. 1993. Moment-based criteria for determining bioequivalence. Biometrika, 80, 835–846.
206. Hollander, M. and Wolfe, D.A. 1973. Nonparametrics Statistical Methods. John Wiley & Sons, New York.
207. Holt, J.D. and Prentice, R.L. 1974. Survival analysis in twin studies and matched-pair experiments. Biometrika, 61, 17–30.
208. Hothorn, L. and Oberdoerfer, R. 2006. Statistical analysis used in the nutritional assessment of novel food using the proof of safety. Regulatory Toxicology and Pharmacology, 44, 125–135.
209. Howe, W.G. 1974. Approximate confidence limit on mean of X þ Y where X and Y are two tabled independent random variables. Journal of the American Statistical Association, 69, 789–794.
210. Hoyle, M.H. 1968. The estimation of variances after using a Gaussinating transformation. The Annals of Mathematical Statistics, 39, 1125–1143.
211. Hsu, H.C. and Lu, H.L. 1997. On confidence limits associated with Chow and Shao’s joint confidence region approach for assessment of bioequivalence. Journal of Biopharmaceutical Statistics, 7, 125–134.
212. Hsuan, F.C. and Reeve, R. 2003. Assessing individual bioequivalence with higher-order cross-over designs: A unified procedure. Statistics in Medicine, 22, 2847–2860.
213. Hsu, J.C., Hwang, J.T.G., Liu, H.K., and Ruberg, S.J. 1994. Confidence intervals associated with tests for bioequivalence. Biometrika, 81, 103–114.
214. Huitson, A., Poloniecki, J., Hews, R., and Barker, N. 1982. A review of cross-over trials. Statistician, 31, 71–80.
215. Huque, M. and Dubey, S.D. 1990. A three arm design and analysis for clinical trials in establishing therapeutic equivalence with clinical endpoints. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Anaheim, California, pp. 91–98.
216. Huster, W.J., Brookmeyer, R., and Self, S.G. 1989. Model paired survival data with covariates. Biometrics, 45, 145–156.
217. Hwang, J.T.G. and Wang, W. 1997. The validity of the test of individual bioequivalence ratios. Biometrika, 84, 893–900.
218. Hyslop, T., Hsuan, F., and Holder, D.J. 2000. A small sample confidence interval approach to assess individual bioequivalence. Statistics in Medicine, 19, 2885–2897.
219. ICH 1996. Q5C Guideline on Quality of Biotechnological Products: Stability Testing of Biotechnological=Biological Products. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the US Food and Drug Administration, Rockville, MD.
220. ICH E5 1998. International Conference on Harmonization Tripartite Guidance E5, Ethnic Factors in the Acceptability of Foreign Data; the U.S. Federal Register, 83, 31790–31796.
221. ICH 1999. Q6B Guideline on Test Procedures and Acceptance Criteria for aBiotechno-logical=Biological Products. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
222. ICH 2005. Q5E Guideline on Comparability of Biotechnological=Biological Products Subject to Changes in Their Manufacturing Process. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
223. Jacques, J.A. 1972. Compartmental Analysis in Biology and Medicine. Elsevier, New York.
224. The Japanese National Institute of Health Sciences 1997. Guideline for Bioequivalence Studies of Generic Drugs.
225. Jelliffe, R.W., Gomis, P., and Schumitzky, A. 1990. A population model of gentamicin made with a new nonparametric EM algorithm. Technical Report 90-4, USC.
226. Jennrich, R.I. and Schluchter, M.D. 1986. Unbalanced repeated measures models with structural covariance matrices. Biometrics, 42, 805–820.
227. John, P.W.M. 1971. Statistical Design and Analysis of Experiments. Macmillan, New York.
228. Johnson, R.A. and Wichern, D.W. 1982. Applied Multivariate Statistical Analysis. Prentice Hall, Englewood Cliffs, NJ.
229. Johnson, N.E., Wade, J.R., and Karlson, M.O. 1996. Comparison of some practical sampling strategies for population pharmacokinetic studies. J. Pharmacokinet. Biopharm., 24, 245–272.
230. Jones, B. and Kenward, M.G. 1989. Design and Analysis of Crossover Trials. 1st edn., Chapman & Hall, London, UK.
231. Jones, B. and Kenward, M.G. 2003. Design and Analysis of Crossover Trials. 2nd ed., Chapman & Hall, London, UK.
232. Jung, S.H. and Su, J.Q. 1995. Non-parametric estimation for the difference or ratio of median failure times for period observations. Statistics in Medicine, 14, 275–281.
233. Kalbfleisch, J.P. and Prentice, R.L. 1980. The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York.
234. Karalis, V., Symillides, M., and Macheras, P. 2004. Novel scaled average bioequivalence limits based on GMR and variability considerations. Pharmaceutical Research, 21, 1933–1942.
235. Karlson, M.O. and Sheiner, L.B. 1993. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm., 21, 735–750.
236. Keida, T., Hayashi, N., and Kawashima, M. 2006. Application of the food and drug administration (FDA) bioequivalent guidance of topical dermatologic corticosteroids in yell-skinned Japanese population: Validation study using a chromameter. Journal of Dermatology, 33, 684–691.
237. Kendall, M.G. and Stuart, A. 1979. The Advance Theory of Statistics. Vol. II, Griffen, London, UK.
238. Kershner, R.P. and Federer, W.T. 1981. Two-treatment crossover design for estimating a variety of effects. Journal of the American Statistical Association, 76, 612–618.
239. Ki, F.Y., Liu, J.P., Wang, W., and Chow, S.C. 1995. The impact of outlying subjects on decision of bioequivalence. Journal of Biopharmaceutical Statistics, 5, 71–94.
240. Kimanani, E.K. and Potvin, D. 1997. A parametric confidence interval for a moment-based scaled criterion for individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics, 25, 595–614.
241. Kirkwood, T.B.L. 1981. Bioequivalence testing—a need to rethink. Biometrics, 37, 589–591.
242. Koch, G.G. 1972. The use of nonparametric methods in the statistical analysis of the two-period change-over design. Biometrics, 28, 577–584.
243. Koch, G.G. and Edwards, S. 1988. Clinical efficacy trials with categorical data. In: Biopharmaceutical Statistical for Drug Development, Peace, K. (Ed.), Marcel Dekker, New York, pp. 403–457.
244. Korn, E.L., Alber, P.S., and McShane, L.M. 2005. Assessing surrogated as trial endpoints using mixed models. Statistics in Medicine, 24, 163–182.
245. Kunin, C.M. 1966. Absorption, distribution, excretion and fate of kanamycin. Annals of the New York Academy of Sciences, 132, 811.
246. Laird, N.M. and Ware, J.H. 1982. Random effects models for longitudinal data. Biometrics, 38, 963–974.
247. Land, C.E. 1988. Hypothesis tests for interval estimates. In: Lognormal Distribution, Crow, E.L. and Shimizu, K. (Eds.), Marcel Dekker, New York, pp. 87–112.
248. Landowski, C.P., Sun, D., Foster, D.R., Menon, S.S., Barnett, J.L., Welage, L.S., Ramachandran, C., and Amidon, G.L. 2003. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. Journal of Pharmacology and Experimental Therapeutics, 306, 778–786.
249. Laska, E.M. and Meisner, M. 1985. A variational approach to optimal two-treatment crossover designs: Applications to carryover effect methods. Journal of the American Statistical Association, 80, 704–710.
250. Laska, E.M., Meisner, M., and Kushner, H.B. 1983. Optimal crossover designs in the presence of carryover effects. Biometrics, 39, 1089–1091.
251. Lasserre, V. 1991. Determination of optimal designs using linear models in crossover trials. Statistics in Medicine, 10, 909–924.
252. Lee, A.F.S. and Fineberg, N.S. 1991. A fitted test for the Behrens–Fisher problem. Communications in Statistics—Theory and Methods, 20, 653–666.
253. Lee, Y., Shao, J., Chow, S.C., and Wang, H. 2002. Tests for inter-subject and total variabilities under crossover designs. Journal of Biopharmaceutical Statistics, 12, 503–534.
254. Lee, Y., Shao, J., and Chow, S.C. 2004. Modified large-sample confidence intervals for linear combinations of variance components: Extension, theory and application. Journal of the American Statistical Association, 99, 467–478.
255. Leeson, L.J. 1995. In vitro=vivo correlation. Drug Information Journal, 29, 903–915.
256. Lehmann, E.L. 1975. Nonparametrics: Statistical Methods Based on Ranks. Holden-Day, San Francisco, CA.
257. Lehmann, E.L. and Romano, J.P. 2005. Testing Statistical Hypotheses. Springer, New York.
258. Levy, N.W. 1986. Bioequivalence of solid oral dosage forms. A presentation to the U.S. Food and Drug Administration Hearing on Bioequivalence of Solid Oral Dosage Forms, September 29–October 1, Pharmaceutical Manufacturer Association, Section II, 9–11.
259. Liang, K.Y. and Zeger, S.L. 1986. Longitudinal data analysis using generalized linear models. Biometrika, 73, 13–22.
260. Lin, J.S., Chow, S.C., and Tse, S.K. 1991. A SAS procedure for outlier detection in bioavailability=bioequivalence studies. Proceedings of the 16th SAS Users Group International Conference, New Orleans, Louisiana, pp. 1433–1437.
261. Lin, T.L. and Tsong, Y. 1990. Removal of a statistical outlier—impact on the subsequent statistical test. Presented at Joint Statistical Meetings, Anaheim, CA.
262. Lindley, D.V. 1965. Introduction to Probability and Statistics for a Bayesian Viewpoint, Part II Inference. Cambridge University Press, Cambridge, UK.
263. Lindsey, J.K. 1993. Models of Repeated Measurements. Oxford University Press, Oxford, UK.
264. Lindstrom, M.J. and Bates, D.M. 1990. Nonlinear mixed effects models for repeated measures data. Biometrics, 46, 673–687.
265. Liu, J.P. 1991. Bioequivalence and intrasubject variability. Journal of Biopharmaceutical Statistics, 1, 205–219.
266. Liu, J.P. 1995. Use of the repeated cross-over designs in assessing bioequivalence. Statistics in Medicine, 14, 1067–1078.
267. Liu, J.P. 1998. Statistical evaluation of individual bioequivalence. Communications in Statistics—Theory and Methods, 27, 1433–1451.
268. Liu, J.P. 2004. Bridging bioequivalence studies. Journal of Biopharmaceutical Statistics, 14, 857–867.
269. Liu, J.P. and Chow, S.C. 1992a. On power calculation of Schuirmann’s two one-sided tests procedure in bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics, 20, 101–104.
270. Liu, J.P. and Chow, S.C. 1992b. On assessment of bioequivalence in variability of bioavailability. Communications in Statistics—Theory and Methods, 21, 2591–2608.
271. Liu, J.P. and Chow, S.C. 1993. On assessment of bioequivalence for drugs with negligible plasma levels. Biometrical Journal, 35, 109–123.
272. Liu, J.P. and Chow, S.C. 1995. Replicated cross-over designs in bioavailability and bioequivalence trials. Drug Information Journal, 29, 871–884.
273. Liu, J.P. and Chow, S.C. 1996. Discussion of bioequivalence trials, intersection—union tests, and equivalence confidence sets, by Berger and Hsu. Statistical Science, 11, 306–312.
274. Liu, J.P. and Chow, S.C. 1997a. Some thoughts on individual bioequivalence. Journal of Biopharmaceutical Statistics, 7, 41–48.
275. Liu, J.P. and Chow, S.C. 1997b. A two one-sided tests procedure for assessing individual bioequivalence. Journal of Biopharmaceutical Statistics, 7, 49–61.
276. Liu, J.P. and Chow, S.C. 2005a. Minimum therapeutically effective dose. In: Encyclopedia of Biostatistics, Armitage, P. and Colton, T. (Eds.), 2nd ed., Vol. 5. John Wiley & Sons, New York, pp. 3249–3251.
277. Liu, J.P. and Chow, S.C. 2005b. Median effective dose. In: Encyclopedia of Biostatistics, Armitage, P. and Colton, T. (Eds.), 2nd ed., Vol. 5. John Wiley & Sons, New York, pp. 3104–3117.
278. Liu, J.P. and Weng, C.S. 1991. Detection of outlying data in bioavailability=bioequivalence studies. Statistics in Medicine, 10, 1375–1389.
279. Liu, J.P. and Weng, C.S. 1992. Estimation of direct formulation effect under log-normal distribution in bioavailability=bioequivalence studies. Statistics in Medicine, 11, 881–896.
280. Liu, J.P. and Weng, C.S. 1993. Evaluation of parametric and nonparametric two one-sided tests procedures for assessing bioequivalence of average bioavailability, Journal of Biopharmaceutical Statistics, 3, 85–102.
281. Liu, J.P. and Weng, C.S. 1994. Estimation of log-transformation in assessing bioequivalence. Communications in Statistics—Theory and Methods, 23, 421–434.
282. Liu, J.P. and Weng, C.S. 1995. Bias of two one-sided tests procedures in assessment of bioequivalence. Statistics in Medicine, 14, 853–861.
283. 2 as a criterion for assessment of similarity between dissolution profiles. Drug Information Journal, 31, 1255–1271.
284. Locke, C.S. 1984. An exact confidence interval for untransformed data for the ratio of two formulation means. Journal of Pharmacokinetics and Biopharmaceutics, 12, 649–655.
285. Lund, R.E. 1975. Tables for an approximate test for outliers in linear models. Technometrics, 17, 473–476.
286. Ma, M.C., Lin, R.P., and Liu, J.P. 1999. Statistical evaluation of dissolution similarity. Statistica Sinica, 9, 1011–1027.
287. Ma, M.C., Wang, B.B.C, Liu, J.P., and Tsong, Y. 2000. On assessment of similarity between dissolution profiles. Journal of Biopharmaceutical Statistics, 10, 229–249.
288. Mallet, A. 1986. A maximum likelihood estimation method for random coefficient regression models. Biometrika, 73, 645–656.
289. Mandallaz, D. and Mau, J. 1981. Comparison of different methods for decision-making in bioequivalence assessment. Biometrics, 37, 213–222.
290. Mann, H.B. and Whitney, D.R. 1947. On a test of whether one or two random variables is stochastically larger than the other. The Annals of Mathematical Statistics, 18, 50–60.
291. Mantel, N. 1977. Do we want confidence interval symmetric about the null value? Biometrics, 33, 759–760.
292. Martinez, M.N. and Jackson, A.J. 1991. Suitability of various noninfinity area under the plasma concentration–time curve (AUC) estimates for use in bioequivalence determination: Relationship to AUC from zero to time infinity (AUC0-inf). Pharmaceutical Research, 18, 512–517.
293. McCulloch, C.E. 1987. Tests for equality of variances with paired data. Communications in Statistics—Theory and Methods, 16, 1377–1391.
294. McNally, R.J., Iyer, H., and Mathew, T. 2003. Tests for individual and population bioequivalence based on generalized p-values. Statistics in Medicine, 22, 31–53.
295. McQuarrie, D.A. 1967. Stochastic approach to chemical kinetics. Journal of Applied Probability, 4, 413–478.
296. Meeting transcript of the U.S. FDA Advisory Committee for Pharmaceutical Science, August 15–16, 1996, Gaithersburg, MD.
297. Mehran, F. 1973. Variance of the MVUE for the lognormal mean. Journal of the American Statistical Association, 67, 726–727.
298. Mentre, F., Mallet, A., and Baccar, D. 1997. Optimal design in random-effects regression models. Biometrika, 84, 429–442.
299. Metzler, C.M. 1974. Bioavailability: A problem in equivalence. Biometrics, 30, 309–317.
300. Metzler, C.M. 1988. Statistical methods for deciding bioequivalence of formulations. In: Oral Substained Released Formulations: Design and Evaluation, Yacobi, A. and Halperin-Walega, E. (Eds.), Pergamon Press, New York, pp. 217–238.
301. Metzler, C.M. and Huang, D.C. 1983. Statistical methods for bioavailability and bioequivalence. Clinical Research Practices and Drug Regulatory Affairs, 1, 109–132.
302. Midha, K.K., Rawson, M.I., and Hubbard, J.W. 1997. Individual and average bioequivalence of high variability drugs and drug products. Journal of Pharmaceutical Sciences, 86, 1193–1197.
303. Mohandoss, E. and Chow, S.C. 1995. A SAS macro for assessment of variability in bioequivalence trials. Proceedings of the 20th SAS User Group International Conference, pp. 1263–1267, Orlando, Florida.
304. Mohandoss, E., Chow, S.C., and Ki, F.Y.C. 1995. Application of Williams’ design for bioequivalence trials. Drug Information Journal, 29, 1029–1038.
305. Moore, J.W. and Flanner, H.H. 1996. Mathematical comparison of curves with an emphasis on dissolution profiles. Pharmaceutical Technology, 20, 64–74.
306. Morgan, W.A. 1939. A test for the significance of the difference between the two variances in a sample from a normal bivariate population. Biometrika, 31, 13–19.
307. Müller, P. and Rosner, G.L. 1997. A Bayesian population model with hierarchical mixture priors applied to blood count data. Journal of American Statistical Association, 92, 1279–1292.
308. Müller-Cohrs, J. 1990. The power of the Anderson–Hauck test and the double t-test. Biometrical Journal, 32, 259–266.
309. Munk, A., Hwang, J.T.G., and Brown, L.D. 2000. Testing average equivalence—finding a compromise between theory and practice. Biometrical Journal, 42, 531–552.
310. Nedelman, J.R. 2005. On some disadvantages of the population approach. The AAPS Journal, 7, E374–E382.
311. Neyman, J. and Scott, E.L. 1960. Correction for bias introduced by a transformation of variables. The Annals of Mathematical Statistics, 31, 643–655.
312. O’Brien, P.C. and Fleming, T.R. 1987. A paired Prentice–Wilcoxon test for censored paired data. Biometrics, 43, 169–180.
313. Organization for Economic Cooperation and Development (OECD) 2001. Consensus Document on Key Nutrients and Key Toxicants in Low Erucic Acid Rapeseed (Canola), Series of the Safety of Novel Foods and Feeds No. 1, ENV=JM=MONO(2001)13.
314. Oser, B.L., Melnick, D., and Hochberg, M. 1945. Physiological availability of the vitamins— study of methods for determining availability in pharmaceutical products. Industrial and Engineering Chemistry, Analytical Edition, 17, 401–411.
315. OTA 1974. Drug Bioequivalence. A report of the Office of Technology Assessment Drug Bioequivalence Study Panel. United States Congress. Washington, D.C.
316. Ott, L. 1984. An Introduction to Statistical Method and Data Analysis. 2nd ed., Duxbury Press, Boston.
317. Owen, D.B. 1965. A special case of a noncentral t distribution. Biometrika, 52, 437–446.
318. Patel, H.I. 1994. Dose–response in pharmacokinetics. Communications in Statistics—Theory and Methods, 23, 451–465.
319. Patil, V.H. 1965. Approximation to the Behrens–Fisher distributions. Biometrika, 52, 267–271.
320. Patnaik, R.N. 1996. Individual bioequivalence: Pharmacokinetic data—replicated designs. Presented at the Meeting of the Advisory Meeting for Pharmaceutical Science, Holiday Inn, Gaithersburg, MD, August 15, 1996.
321. Patnaik, R.N., Lesko, L.J., Chen, M.L., Williams, R.L., and the FDA Individual Bioequivalence Working Group. 1997. Individual bioequivalence—new concepts in the statistical assessment of bioequivalence metrics. Clinical Pharmacokinetics, 33, 1–6.
322. Peace, K.E. 1986. Estimating the degree of equivalence and non-equivalence: An alternative to bioequivalence testing. Proceedings of the Biopharmaceutical section of the American Statistical Association, St. Louis, Missouri, pp. 63–69.
323. Peace, K.E. 1990. Statistical Issues in Drug Research and Development. Marcel Dekker, New York.
324. Phillips, K.F. 1990. Power of the two one-sided tests procedure in bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics, 18, 137–144.
325. Phillips, K.F. 1993. A log-normal model for individual bioequivalence. Journal of Biopharmaceutical Statistics, 3, 185–201.
326. Pinheiro, J.C. and Bates, D.M. 1995. Approximations to the log-likelihood function in the nonlinear mixed effects model. Journal of Computational and Graphical Statistics, 4, 12–35.
327. Pinheiro, J.C. and Bates, D.M. 2000. Mixed Effects Models in S and S-Plus. Springer, New York.
328. Pitman, E.J.G. 1939. A note on normal correlation. Biometrika, 31, 9–12.
329. Pocock, S.J. 1983. Clinical Trials—A Practical Approach. John Wiley & Sons, New York.
330. Poli, J.E. and McLean, A.M. 2001. Novel direct curve comparison metrics for bioequivalence. Pharmaceutical Research, 18, 734–741.
331. Pong, A.P. and Chow, S.C. 1996. A SAS program for the assessment of unbalanced data in two-sequence, three-period crossover trials. Proceedings of the 21st SAS User Group International Conference, Chicago, Illinois, pp. 1420–1425.
332. Purich, E. 1980. Bioavailability=bioequivalence regulations: An FDA perspective. In: Drug Absorption and Disposition: Statistical Considerations, Albert, K.S. (Ed.), American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Washington, DC, pp. 115–137.
333. Quiroz, J., Ting, N., Wei, G.C., and Burdick, R.K. 2002. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs. Statistics in Medicine, 21, 1825–1847.
334. Racine-Poon, A. 1985. A Bayesian approach to nonlinear random effects models. Biometrics, 41, 1015–1023.
335. Racine-Poon, A. and Smith, A.M.F. 1990. Population models. In: Statistical Methodology in Pharmaceutical Sciences, Berry, D.A. (Ed.), Dekker, New York, pp. 139–162.
336. Racine-Poon, A., Grieve, A.P., Fluehler, H., and Smith, A.F. 1986. Bayesian methods in practice experiences in the pharmaceutical industry (with discussion). Applied Statistics, 35, 93–150.
337. Racine-Poon, A., Grieve, A.P., Fluehler, H., and Smith, A.F. 1987. A two-stage procedure for bioequivalence studies. Biometrics, 43, 847–856.
338. Ramsay, T. and Elkum, N. 2005. A comparison of four different methods for outlier detection in bioequivalence studies. Journal of Biopharmaceutical Statistics, 15, 43–52.
339. Randles, R.H. and Wolfe, D.A. 1979. Introduction to the Theory of Nonparametric Statistics. John Wiley & Sons, New York.
340. Ratkowsky, D.A., Evans, M.A., and Alldredge, I.R. 1993. Cross-Over Experiments. Marcel Dekker, New York.
341. Retout, S. and Mentre, F. 2003. Further development of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. Journal of Biopharmaceutical Statistics, 13, 209–227.
342. Richardson, B.A. and Flack, V.F. 1996. The analysis of incomplete data in the three-period two-treatment cross-over design for clinical trials. Statistics in Medicine, 15, 127–143.
343. Rocke, D.M. 1984. On testing for bioequivalence. Biometrics, 40, 225–230.
344. Rodda, B.E. 1986. Bioequivalence of solid oral dosage forms. A presentation to the U.S. Food and Drug Administration Hearing on Bioequivalence of Solid Oral Dosage Forms, September 29–October 1, Pharmaceutical Manufacturers Association, Section III, pp. 12–15.
345. Rodda, B.E. and Davis, R.L. 1980. Determining the probability of an important difference in bioavailability. Clinical Pharmacology and Therapeutics, 28, 247–252.
346. Rothmann, M., Li, N., Chen, G., Chi, G.Y.H., Temple, R., and Tsou, H.H. 2003. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine, 22, 239–264.
347. Rowland, M. and Tozer, T.N. 1980. Clinical Pharmacokinetics Concepts and Applications. Lea & Febiger, Philadelphia, PA.
348. Roy, A. and Ette, E.I. 2005. A pragmatic approach to the design of population pharmacokinetic studies. The AAPS Journal, 7, E408–E419.
349. Ryde, M., Huitfeldt, B., and Pettersson, R. 1991. Relative bioavailability of Olsalazine from tables and capsules: A drug targeted for local effect in the colon. Biopharmaceutics and Drug Disposition, 12, 233–246.
350. Saranadasa, H. and Krishnamoorthy, K. 2005. A multivariate test for similarity of two dissolution profile. Journal of Biopharmaceutical Statistics, 15, 265–278.
351. Sargent, D.J., Weiand, H.S., Haller, D.G., Gray, R., Beneditti, J.K., Buyre, M., Labianca, Roberto, Seitz, J.F., O’Callaghan, C.J., Francini, G., Grothey, A., O’Connel, M., Catalano, P.J., Blaube, C.D., Kerr, D., Green, E., Wolmark, N., Andre, T., Goldberg, R.M., and Gramont, A.De. 2005. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies. Journal of Clinical Oncology, 23, 8864–8870.
352. SAS 2005. Statistical Analysis System. SAS User’s Guide: Statistics, Version 9. SAS Institute, Cary, NC.
353. Saul, S. 2007. More generics slow rias in drug prices, August 8, 2007, The New York Times.
354. Schall, R. 1995. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar. Biometrics, 51, 615–626.
355. Schall, R. and Luus, H.G. 1993. On population and individual bioequivalence. Statistics in Medicine, 12, 1109–1124.
356. Schuirmann, D.J. 1981. On hypothesis testing to determine if the mean of a normal distribution is continued in a known interval. Biometrics, 37, 617 [abstract].
357. Schuirmann, D.J. 1987. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15, 657–680.
358. Schuirmann, D.J. 1989. Confidence intervals for the ratio of two means from a cross-over study. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Washington, DC, pp. 121–126.
359. Schumitzky, A. 1990. Nonparametric EM algorithms for estimating prior distributions. Technical Reports, 90-2, USC.
360. Searle, S.R. 1971. Linear Models. John Wiley & Sons, New York.
361. Searle, S.R., Casella, G., and McCulloch, C.E. 1992, Variance Components. John Wiley & Sons, New York.
362. Selwyn, M.R. and Hall, N.R. 1984. On Bayesian methods for bioequivalence. Biometrics, 40, 1103–1108.
363. Selwyn, M.R., Dempster, A.P., and Hall, N.R. 1981. A Bayesian approach to bioequivalence for the 2 x 2 changeover design. Biometrics, 37, 11–21.
364. Senn, S. 1993. Cross-over Trials in Clinical Research. John Wiley & Sons, New York.
365. Serfling, R.J. 1980. Approximation Theorems of Mathematical Statistics, Wiley, New York.
366. 2. Pharmaceutical Research, 15, 889–896.
367. Shao, J., Chow, S.C., and Ju, H.L. 1995. Analysis of missing data for replicated crossover design. Journal of China Statistical Association, 33, 215–233.
368. Shao, J., Chow, S.C., and Wang, B. 2000. Bootstrap methods for individual bioequivalence. Statistics in Medicine, 19, 2741–2754.
369. Shapiro, S.S. and Wilk, M.B. 1965. An analysis of variance test for normality (complete samples). Biometrika, 52, 591–611.
370. Sheiner, L.B. 1992. Bioequivalence revisited. Statistics in Medicine, 11, 1777–1788.
371. Sheiner, L.B. 1997. Learning vs confirming in clinical drug development. Clin. Pharmacol. Ther., 61, 275–291.
372. Sheiner, L.B. and Beal, S.L. 1980. Evaluation of methods for estimating population pharmacokinetic parameters, I. Michaelis–Menten model: Routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 8, 553–571.
373. Sheiner, L.B. and Beal, S.L. 1981. Evaluation of methods for estimating population pharmacokinetic parameters, II. Biexponential model and experimental pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics, 9, 635–651.
374. Sheiner, L.B. and Beal, S.L. 1983. Evaluation of methods for estimating population pharmacokinetic parameters, III. Monoexponential model and routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 11, 303–319.
375. Sheiner, L.B., Beal, S.L. and Dunne, A. 1997. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. Journal of American Statistical Association, 92, 1235–1244.
376. Sheiner, L.B., Rosenberg, B., and Melmon, K.L. 1972. Modelling of individual pharmacokinetics for computer-aided drug dosage. Computer and Biomedical Research, 5, 441–459.
377. Sheiner, L.B., Rosenberg, B., and Marathe, V.V. 1977. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 5, 445–479.
378. Shimizu, K. 1988. Point estimation. In: Lognormal Distribution, Crow, E.L. and Shimizu, K. (Eds.), Marcel Dekker, New York, pp. 27–86.
379. Shirley, E. 1976. The use of confidence intervals in biopharmaceutics. Journal of Pharmacy and Pharmacology, 28, 312–313.
380. Simon, R. 1999. Bayesian design and analysis of active control clinical trials. Biometrics, 55, 484–487.
381. Smith, S.J. 1988. Evaluating the efficiency of the D distribution mean estimator. Biometics, 44, 485–493.
382. Smith, T. 1986. Statistical methods—dose proportionality. Technical Report, Ayerst Laboratories, New York.
383. Smith, B.P., Vandenhende, F.R., deSante, K.A., Welch, P.A., Callaghan, J.T., and Forgne, S.T. 2000. Confidence interval criteria for assessment of dose proportionality. Pharmaceutical Research, 17, 1278–1283.
384. Snedecor, G.W. and Cochran, W.G. 1980. Statistical Methods. 7th ed., Iowa State University Press, Ames, IA.
385. Snee, R.D. 1972. On the analysis of response curve data. Technometrics, 14, 47–62.
386. Srikantan, K.S. 1961. Testing a single outlier in a regression model. Sankhyá, A, 23, 251–260.
387. Srinivasan, R. and Langenberg, P. 1986. A two-stage procedure with controlled error probabilities for testing bioequivalence. Biometrical Journal, 28, 825–833.
388. Steimer, J.L., Mallet, A., Golmard, J.F., and Boisvieux, J.F. 1984. Alternative approaches to estimation of population pharmacokinetic parameters; comparison with the nonlinear mixed effect model. Drug Metabolism Reviews, 15, 265–292.
389. Steinijans, V.W. and Diletti, E. 1983. Statistical analysis of bioavailability studies: Parametric and nonparametric confidence intervals. European Journal of Clinical Pharmacology, 24, 127–136.
390. Steinijans, V.W. and Diletti, E. 1985. Generalization of distribution-free confidence intervals for bioavailability ratios. European Journal of Clinical Pharmacology, 28, 85–88.
391. Steinijans, V.W. and Shulz, H.U. 1992. Bioequivalence Assessment: Methods and Applications of the International Journal of Clinical Pharmacology Therapy and Toxicology, 30, Suppl. 1, S1-6.
392. Sun, H., Ette, E.L., and Ludden, T.M. 1996. On the recording of sampling times and parameter estimation from repeated measures of pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics, 24, 637–650.
393. Tempelman, R.J. 2004. Experimental design and statistical model for classical and bioequivalence hypothesis testing with an application to dairy nutrition studies, Journal of Animal Science, 82(E. Suppl.), E162–E172.
394. The Numerical Algorithm Group. 2008. Oxford, U.K. website: www.nag.co.uk.
395. Thiyagarajan, B. and Dobbins, T.W. 1987. An assessment of the 75=75 rule in bioequivalence. Proceedings of the Biopharmaceutical section of the American Statistical Association, San Francisco, California. pp. 143–148.
396. 2-distribution, Biometrica, 32, 188–189.
397. Ting, N., Burdick, R.K., Graybill, F.A., Jeyaratnam, S., and Lu, T.-F.C. 1990. Confidence intervals on linear combinations of variance components that are unrestricted in sign. Journal of Statistical Computation and Simulation, 35, 135–143.
398. Tothfalusi, L. and Endrenyi, L. 2003. Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharmaceutical Research, 20, 382–389.
399. Tse, S.K. 1990. A comparison of interval estimation procedures in bioavailability= bioequivalence. Proceedings of the Biopharmaceutical section of the American Statistical Association, Anaheim, California, pp. 43–46.
400. Tsong, Y. 1995. Statistical assessment of mean differences between two dissolution data sets. Presented at the 1995 Drug Information Association Dissolution Workshop, Rockville, MD.
401. Tsong, Y., Hammerstorm, T., Sathe, P., and Shah, V.P. 1996. Statistical assessment of mean differences between two dissolution data sets. Drug Information Journal, 30, 1105–1112.
402. Tsui, K.W. and Weeranhandi, S. 1989. Generalized p-values in significance testing of hypotheses in the presence of nuisance parameters. Journal of American Statistical Association, 84, 602–607.
403. Turkey, J.W. 1951. Components in regression. Biometrics, 7, 33–69.
404. Vonesh, E.F. 1996. A note on the use of Laplace’s approximation for nonlinear mixed-effects models. Biometrika, 83, 447–452.
405. Vonesh, E.F. and Chinchilli, V.M. 1997. Linear and Nonlinear Models for the Analysis of Repeated Measurements. Marcel Dekker, New York.
406. Vuorinen, J. 1997. A practical approach for the assessment of bioequivalence under selected higher-order cross-over designs. Statistics in Medicine, 16, 2229–2243.
407. Vuorinen, J. and Turunen, J. 1996. A three-step procedure for assessing bioequivalence in the general mixed linear framework. Statistics in Medicine, 15, 2635–2655.
408. Wagner, J.G. 1971. Biopharmaceutics and Relevant Pharmacokinetics. Drug Intelligence Publications, Hamilton, IL.
409. Wagner, J.G. 1975. Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Hamilton, IL.
410. Wakefield, J. 1996. The Bayesian analysis of population pharmacokinetic models. Journal of American Statistical Association, 91, 62–75.
411. Walsh, J.E. 1949. Some significance tests for the median which are valid under very general conditions. The Annals of Mathematical Statistics, 20, 64–81.
412. Wang, C.M. 1990. On the lower bound of confidence coefficients for a confidence interval on variance components. Biometrics, 46, 187–192.
413. Wang, H., Zhang, Y., Shao, J., and Chow, S.C. 2000. In vitro bioequivalence testing. In: Encyclopedia of Biopharmaceutical Statistics, Chow, S.C. (Ed.), 2nd ed., Marcel Dekker, New York.
414. Wang, J. and Endrenyi, L. 1992. A computationally efficient approach for the design of population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics, 20, 279–294.
415. Wang, S.J., Hung, J.H.M., and Tsong, Y. 2002. Utility and pitfalls of some statistical methods in active control trials. Controlled Clinical Trials, 23, 15–28.
416. Wang, S.J. and Hung, J.H.M. 2003. TACT method for noninferiority testing in active controlled trials. Statistics in Medicine, 22, 227–238.
417. Wang, W. 1997. Optimal unbiased tests for equivalence in intrasubject variability. Journal of the American Statistical Association, 88, 939–946.
418. Wang, W. and Chow, S.C. 2003. Examining outlying subjects and outlying records in bioequivalence trials. Journal of Biopharmaceutical Statistics, 13, 43–56.
419. Wang, W., Hwang, J.T., and DasGupta, A. 1999. Statistical tests for multivariate bioequivalence. Biometrika, 86, 395–402.
420. Wang, W.P., Chow, S.C., and Wei, W. 1995. On likelihood distance for outliers detection. Journal of Biopharmaceutical Statistics, 5, 307–322.
421. Wang, W.P., Hsuan, F., and Chow, S.C. 1996. Patient compliance and fluctuation of the serum drug concentration. Statistics in Medicine, 15, 659–669.
422. Wang, W.P., Hsuan, F., and Chow, S.C. 1997. An adjusted two one-sided t-test for bioequivalence trials with multiple doses. Journal of Biopharmaceutical Statistics, 7, 157–170.
423. Ware, J.H. 1985. Linear models for the analysis of longitudinal studies. American Statistical Association, 39, 95–101.
424. Ware, J.H., Mosteller, F., and Ingelfinger, J.A. 1986. p-Values. In: Medical Use of Statistics, Bailar, J.C. and Mosteller, F. (Eds.), NEJM Books, Waltham, MA.
425. Wearahandi, S. 1995. Exact Statistical Method for Data Analysis. Springer, New York.
426. Weiner, D. 1989. Bioavailability. Notes on the training course for new clinical statisticians sponsored by the Biostatistics Subsections of Pharmaceutical Manufacture Association, March, 1989, Washington, DC.
427. Wellek, S. 1993. Basing the analysis of comparative bioavailability trials on an individualized statistical definition of equivalence. Biometrical Journal, 35, 47–55.
428. Westlake, W.J. 1972. Use of confidence intervals in analysis of comparative bioavailability trials. Journal of Pharmaceutical Science, 61, 1340–1341.
429. Westlake, W.J. 1973. The design and analysis of comparative blood-level trials. In: Current Concepts in the Pharmaceutical Sciences, Swarbrick, J. (Ed.), Lea & Febiger, Philadelphia.
430. Westlake, W.J. 1974. The use of balanced incomplete block designs in comparative bioavailability trials. Biometrics, 30, 319–327.
431. Westlake, W.J. 1976. Symmetrical confidence intervals for bioequivalence trials. Biometrics, 32, 741–744.
432. Westlake, W.J. 1979. Statistical aspects of comparative bioavailability trials. Biometrics, 35, 273–280.
433. Westlake, W.J. 1981. Bioequivalence testing—a need to rethink [reader reaction response]. Biometrics, 37, 591–593.
434. Westlake, W.J. 1986. Bioavailability and bioequivalence of pharmaceutical formulations. In: Biopharmaceutical Statistics for Drug Development, Peace, K. (Ed.), Marcel Dekker, New York, pp. 329–352.
435. Wijnard, H.P. and Timmer, C.J. 1983. Mini-computer programs for bioequivalence testing for pharmaceutical drug formulations in two-way crossover studies. Computer Programs in Biomedicine, 17, 73–88.
436. Wilcoxon, F. 1945. Individual comparisons by ranking methods. Biometrics, 1, 80–83.
437. Williams, E.J. 1949. Experimental designs balanced for the residual effects of treatment. Australian Journal of Science and Research, 2, 149–168.
438. Williams, J.S. 1962. A confidence interval for variance components. Biometrika, 49, 278–281.
439. Wolfinger, R. 1993. Covariance structure selection in general mixed models. Communication in Statistics, B, 22, 1079–2006.
440. WHO 2005a. World Health Organization Draft Revision on Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability, Geneva, Switzerland.
441. WHO 2005b. World Health Organization Revision=Update of the Guidance on the Selection of Comparator Pharmaceutical Products for Equivalence Assessment of Interchangeable Multisource (Generic) Products, Geneva, Switzerland.
442. Yee, K.F. 1986. The calculation of probabilities in rejecting bioequivalence. Biometrics, 42, 961–965.
443. Yeh, C.M. and Chiang, T. 1991. Bioavailability in a 3 x 3 crossover study of a combination drug. Presented at 1991 Drug Information Association Statistics Workship. Hilton Head, SC.
444. Yeh, K.C. and Kwan, K.C. 1978. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximations. Journal of Pharmacokinetics and Biopharmaceutics, 6, 79–81.
445. Zeger, S. and Liang, K.Y. 1986. Longitudinal data analysis for discrete and continuous outcomes. Biometrics, 42, 121–130.